HOOK - Hookipa Pharma's HB-200 shows positive clinical efficacy in HPV16+ cancers

HOOKIPA Pharma (HOOK) has reported positive Phase 1 data from its ongoing Phase 1/2 study of HB-200 for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.Up to the March 31 cut-off date, 38 patients with metastatic HPV16+ tumors had received HB-200 therapy: 14 received HB-201, 8 received alternating HB-201/HB-202, and 16 received other regimens.Immunogenicity data for eight patients with head and neck tumors were available at the time of data cut-off.  Arenaviral therapeutic HB-200 therapy induced outstanding tumor-specific CD8+ T cell responses, including an average of 6% and up to 40% of the circulating T cell pool.The data are from the ongoing Phase 1 dose escalation; the recommended Phase 2 dose for HB-200 therapy has yet not been reached. Fifteen patients with metastatic head and neck cancers were eligible for the efficacy analysis: 11 received HB-201 and four received HB-201/HB-202.Of the 15 patients, 93% had target lesion control, including 53%

For further details see:

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers